1 / 15

HEALTHCARE GROUP

HEALTHCARE GROUP. January 17, 2003 Nelson Campbell. FBR. Healthcare Investment Banking. Refinancing Driving Consumer Spending in 2001 and 2002. Key Trends: Interest rates had allowed consumers to extract record amounts of equity via cash-out refinancing.

fagan
Télécharger la présentation

HEALTHCARE GROUP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEALTHCARE GROUP January 17, 2003 Nelson Campbell FBR Healthcare Investment Banking

  2. Refinancing Driving Consumer Spending in 2001 and 2002 • Key Trends: • Interest rates had allowed consumers to extract record amounts of equity via cash-out refinancing. • Increase in available cash drove consumer spending despite 6% unemployment. In 2002, the U.S. economy grew 3%, broadly in line with its long-term trend

  3. The Case for a Capital Spending Recovery in 2003 • Outside of telecom, fears of a broad-based capital stock overhang are overstated. • In 2002, the value of capital stock registered its first annual decline in the post WWII era. • Return on capital is historically high relative to the real cost of capital. • Cash flow growth has recovered while capital spending has not. Source: The Bank Credit Analyst

  4. Looking Forward • The economy will not slide back into recession • Corporate profits will increase • Monetary and fiscal policy will remain very stimulative (the Federal Reserve will not raise interest rates any time soon).

  5. Most of the Pieces are in Place for a Classic Cyclical Bull Market • Liquidity is explosive • Many measures of sentiment have reached depressed levels • Many indicators suggest the economy and corporate earnings are set to recover in the next six months • Stocks led economic rebounds by an average of 4.5 months during the past eight market cycles

  6. The State of The Public Market • Key Trends: • The NASDAQ Composite is down 71.3% since its peak, and down 34.0% since 1/1/99 • The NASDAQ Biotech Index is down 67.3% since its peak, but up 18.2% since 1/1/99 Selected Market Indices 18.2% -4.3% -24.5% -34.0% Source: Bloomberg As of: 1/10/03

  7. Small Cap vs. Large Cap Biotech Stocks • Key Trends: • When the capital markets are weak, investors prefer large cap biotech stocks to small and middle market biotech firms. • The NASDAQ Biotech Index was down 0.6% in 2001, but was down 45% in 2002 and reached its lowest level since 1999 Source: Bloomberg

  8. Recent Drug Failures GenVec - BioBypass, Phase II, Missed Primary Endpoint in peripheral arterial disease Cook/Guidant - Missed Primary Endpoint in restenosis Icos Corp. - Pafase, Phase III, Failed to Show Benefit in severe sepsis Eli Lilly - Ruboxistaurin, PhaseII/III, Missed Primary Endpoint for diabetic retinopathy ConjuChem - CJC-1008, Phase II, Missed Primary Endpoint Transkaryotic Therapies - Replagal, Phase III, Missed Primary Endpoint in renal function Neurogen - NGB97-1, Failed to Show Therapeutic Effect in Treatment of Alzheimer’s disease Alexion Pharmaceuticals - Eculizumab, Phase II Missed Primary Endpoint of proteinura reduction Endo Pharmaceuticals - MorphiDex, Phase III, Missed Primary Endpoint Immune Network - Dapsone, Phase II data Not Significant Schering AG - Estradiol, Non-Approvable Letter Transkaryotic Therapies - Replagal, FDA Meeting Delayed IntraBiotics Pharmaceuticals - Iseganan, Missed Primary Endpoint for oral mucositis during chemotherapy Genmab A/S - HuMax-CD4, Missed Primary Endpoint for rheumatoid arthritis Incara Pharmaceuticals - Deligoparin, Phase II/III trial Missed Primary Endpoint Date Order - Most Recent First 9/02 to Present Source: BioCentury, company reports

  9. Tapping the Public Market: Biotech IPOs • Key Trends: • The spike in financing in 2000 was an anomaly • In 2000, there were 53 biotechnology IPOs which raised $4.2 billion • In 2001, there were 5 biotechnology IPOs which raised $304 million • In 2002, there were 4 biotechnology IPO which raised $592 million Biotech IPOs and the Amount Raised Source: CommScan EquiDesk

  10. Tapping the Public Market: Biotech Secondaries Biotech Secondaries and the Amount Raised • Key Trends: • In 2000, there were 57 biotechnology secondary offerings which raised $16.4 billion • In 2001, there were 29 biotechnology secondary offerings which have raised $2.93 billion • In 2002, there were 11 biotechnology secondary offerings which raised $544.3 million Source: CommScan EquiDesk

  11. U.S. Venture Capital - Biotechnology Investments vs. Total Domestic investments only Source: PWC Money Tree

  12. Financing Summary Biotechnology and Specialty Pharmaceutical Investments

  13. Recent Mergers and Acquisitions in the Biotech Field Acquirer/TargetAnnouncement DateValue Chiron/Matrix Pharmaceutical 1/7/02 $61MM deCODE genetics/MediChem Life Sciences 1/8/02 $83.6MM Collateral Therapeutics/Schering AG 3/20/02 $140.9MM Tibotec-Virco NV/Johnson & Johnson 3/22/02 $320MM Ethypharm/Biovail 4/1/02 $127.8MM Rhein Biotech/Berna Biotech 5/1/02 $225MM Pharmacia/Pfizer 7/15/02 $60 Billion Genset/Serono 7/16/02 $107MM Visible Genetics/Bayer AG 7/23/02 $61.4MM Variagenics/Hyseq 11/11/02 $55.9MM Synaptic/H. Lundbeck 11/21/02 $121MM Triangle/Gilead 12/4/02 $464MM Zentaris/Aeterna 1/1/03 $51.7MM Source: MergerStat

  14. Growth in New Drug Approvals • Key Trends: • There are currently more than 130 biotechnology drug products and vaccines on the market. • There are more than 350 biotechnology drug products and vaccines, targeting more than 200 diseases, in clinical trials. • 30% of biotech companies have less than 1 year of cash and equivalents. • 22% of biotech companies are trading below cash (i.e., their market caps are below the cash on their balance sheets) • The growth in drug approvals from the biotechnology industry points to strong fundamentals. Source: Biotechnology Industry Organization

  15. Growth in Biotechnology Sales and Revenues • Key Trends: • With the growth in drug approvals comes increased drug sales and increased leverage in collaboration negotiations Source: Ernst & Young Annual Biotechnology Industry Reports, Biotechnology Industry Organization

More Related